Base de dados : LILACS
Pesquisa : D05.750.078.562.272 [Categoria DeCS]
Referências encontradas : 111 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 12 ir para página                         

  1 / 111 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-785730
Autor: Taşkinlar, Hakan; Avlan, Dincer; Bahadir, Gokhan Berktug; Delibaş, Ali; Nayci, Ali.
Título: The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux
Fonte: Int. braz. j. urol;42(3):514-520tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose Subureteral injection of bulking agents in the endoscopic treatment of vesicoureteral reflux is widely accepted therapy with high success rates. Although the grade of vesicoureteric reflux and experience of surgeon is the mainstay of this success, the characteristics of augmenting substances may have an effect particularly in the long term. In this retrospective study, we aimed to evaluate the clinical outcomes of the endoscopic treatment of vesicoureteric reflux (VUR) with two different bulking agents: Dextranomer/hyaluronic acid copolymer (Dx/HA) and Polyacrylate polyalcohol copolymer (PPC). Materials and Methods A total 80 patients (49 girls and 31 boys) aged 1-12 years (mean age 5.3 years) underwent endoscopic subureteral injection for correction of VUR last six years. The patients were assigned to two groups: subureteral injections of Dx/HA (45 patients and 57 ureters) and PPC (35 patients and 45 ureters). VUR was grade II in 27 ureters, grade III in 35, grade IV in 22 and grade V in 18 ureters. Results VUR was resolved in 38 (66.6%) of 57 ureters and this equates to VUR correction in 33 (73.3%) of the 45 patients in Dx/HA group. In PPC group, overall success rate was 88.8% (of 40 in 45 ureters). Thus, Thus, this equates to VUR correction in 31 (88.5%) of the 35 patients. Conclusions Our short term data show that two different bulking agent injections provide a high level of reflux resolution and this study revealed that success rate of PPC was significantly higher than Dx/HA with less material.
Descritores: Polímeros/uso terapêutico
Refluxo Vesicoureteral/terapia
Materiais Biocompatíveis/uso terapêutico
Acrilatos/uso terapêutico
Resinas Acrílicas/uso terapêutico
Dextranos/uso terapêutico
Ácido Hialurônico/uso terapêutico
-Próteses e Implantes
Ureter
Reprodutibilidade dos Testes
Estudos Retrospectivos
Seguimentos
Resultado do Tratamento
Ureteroscopia/métodos
Injeções/métodos
Limites: Humanos
Masculino
Feminino
Lactente
Pré-Escolar
Criança
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  2 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975658
Autor: Tekin, Ali; Yagmur, Ismail; Tiryaki, Sibel; Dokumcu, Zafer; Ulman, Ibrahim; Avanoglu, Ali.
Título: Changing bulking agent may require change in injection volume for endoscopic treatment of vesicoureteral reflux
Fonte: Int. braz. j. urol;44(6):1194-1199, Nov.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction: Various bulking agents were utilized for endoscopic correction of VUR. A study reviewing multi-institutional data showed that the amount of injection material has increased over time with the purpose of improving success rates, which also resulted in costs. We noticed an opposite trend in our center since we started using a new bulking agent. The aim of this study was to evaluate evolution of our practice with different bulking agents. Patients and Methods: Records of VUR patients who underwent subureteric injection with polyacrylate polyalcohol copolymer (PPC) and dextronomere hyaluronic acide (DxHA) between 2005 and 2014 were reviewed. Variation of different parameters throughout the study period was evaluated along with the success rate. Success was defined as complete resolution of reflux. Results: A total of 260 patients with 384 refluxing units were included. The success rate was higher in PPC group compared to DxHA group. There was no statistically significant difference between years regarding distribution of VUR grade, body weight, patient height, and age in PPC group. Despite significant reduction in injection volume, success rate did not decrease through the years with PPC. Conclusion: Different bulking agents may require different injection volumes to achieve the same success rate in endoscopic treatment of vesicoureteral reflux. Habits gained with previous experience using other materials should be revised while using a new agent.
Descritores: Polímeros/administração & dosagem
Refluxo Vesicoureteral/terapia
Materiais Biocompatíveis/administração & dosagem
Resinas Acrílicas/administração & dosagem
Dextranos/administração & dosagem
Ácido Hialurônico/administração & dosagem
-Seguimentos
Resultado do Tratamento
Ureteroscopia
Limites: Humanos
Pré-Escolar
Criança
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  3 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975662
Autor: Dalkiliç, Ayhan; Bayar, Göksel; Demirkan, Hasan; Horasanli, Kaya.
Título: The learning curve of sting method for endoscopic injection treatment of vesicoureteral reflux
Fonte: Int. braz. j. urol;44(6):1200-1206, Nov.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: To identify how many endoscopic injection (EI) procedures, STING method, must be performed before reaching an ideal success rate when simulation training has not been received. Materials and Methods: The EI procedures performed by two pediatric urology fellows were investigated. The study excluded patients without primary VUR and those with previous EI or ureteroneocystostomy, lower urinary tract dysfunction, and/or duplicate ureters. The EIs used dextranomer hyaluronate and the STING method, as described by O'Donnell and Puri. Groups number was determined by multiple statistical trials. Statistically significance differences were achieved with one combination that had 35 EI procedures each and with 3 different combination of patients, having 12, 24, and 36 patients, respectively. Therefore, groups were established 12 patients. The first fellow performed 54 EIs, and the second performed 51. Therefore, each of the first fellow's three groups contained 18 EI procedures, and each of the second fellow's 17. Results: The study included 72 patients and 105 ureter units. When the data from both fellows were combined, each of the three groups contained 35 procedures. For the first fellow, the success rates in the first, second, and third groups were 38.3%, 66.6%, and 83.3% (p = 0.02), respectively, and for the second fellow, the success rates were 41.2%, 64.7%, and 82.3% (p = 0.045), respectively. The increased success rates for both fellows were very similar. Conclusions: An acceptable rate of success for EI may be reached after about 20 procedures and a high success rate after about 35-40 procedures.
Descritores: Refluxo Vesicoureteral/terapia
Curva de Aprendizado
Ácido Hialurônico/administração & dosagem
-Estudos Retrospectivos
Dextranos/administração & dosagem
Resultado do Tratamento
Competência Clínica
Cistoscopia
Limites: Humanos
Masculino
Feminino
Lactente
Pré-Escolar
Criança
Adolescente
Responsável: BR1.1 - BIREME


  4 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-954059
Autor: Ozkuvanci, Unsal; Donmez, Muhammet Irfan; Ozgor, Faruk; Erbin, Akif; Pasin, Özge; Muslumanoglu, Ahmet Yaser.
Título: Durasphere® EXP: a non-biodegradable agent for treatment of primary Vesico-Ureteral reflux in children
Fonte: Int. braz. j. urol;44(3):585-590, May-June 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction: Durasphere® EXP (DEXP) is a compound of biocompatible and non--biodegradable particles of zirconium oxide covered with pyrolytic carbon. The aim of this study is to evaluate the durability of off-label use of DEXP in the treatment of primary vesicoureteral reflux in children. Materials and Methods: Patients who underwent subureteric injection of DEXP for the correction of primary VUR were retrospectively reviewed. Patients aged >18 years as well as those who had grade-I or -V VUR, anatomic abnormalities (duplicated system, hutch diverticulum), neurogenic bladder or treatment refractory voiding dysfunction were excluded. Radiologic success was defined as the resolution of VUR at the 3rd month control. Success was radiographically evaluated at the end of the first year. Results: Thirty-eight patients (9 boys, 29 girls; mean age, 6.3±2.7 years) formed the study cohort. Forty-six renal units received DEXP (grade II: 22; grade III: 18; grade IV: 6). Mean volume per ureteric orifice to obtain the mound was 0.70±0.16mL. First con- trol VCUG was done after 3 months in all patients. After the first VCUG, 6 patients had VUR recurrence. Short-term radiologic success of DEXP was 84.2%. Rate of radiologic success at the end of the first year was 69.4% (25/32). Lower age (p:0.006) and lower amount of injected material (p:0.05) were associated with higher success rates at the end of 1 year. Conclusion: This is the first study to assess the outcomes of DEXP for treatment of primary VUR in children. After 1 year of follow-up, DEXP had a 69.4% success rate.
Descritores: Refluxo Vesicoureteral/tratamento farmacológico
Zircônio/uso terapêutico
Materiais Biocompatíveis/uso terapêutico
Glucanos/uso terapêutico
-Recidiva
Refluxo Vesicoureteral/cirurgia
Índice de Gravidade de Doença
Reprodutibilidade dos Testes
Estudos Retrospectivos
Dextranos/uso terapêutico
Resultado do Tratamento
Estatísticas não Paramétricas
Endoscopia/métodos
Ácido Hialurônico/uso terapêutico
Injeções
Limites: Humanos
Masculino
Feminino
Pré-Escolar
Criança
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  5 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1154465
Autor: Sabetkish, Shabnam; Mohseni, Mohammad Javad; Sabetkish, Nastaran; Kajbafzadeh, Abdol-Mohammad.
Título: Local tissue reaction and histopathological characteristics of three different bulking agents: a rabbit model
Fonte: Int. braz. j. urol;47(2):322-332, Mar.-Apr. 2021. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: We assessed the efficacy and safety of a single injection of three bulking agents over the short- and long-term follow-ups in rabbits. Dermal and preputial matrices were compared with Deflux (DxHA) injection. Material and methods: Twenty-four rabbits were divided into three groups. Group I (n=8) underwent the injection of a lyophilized dermal matrix (LDM) beneath the seromuscular layer of the bladder wall. Rabbits in group II (n=8) were injected with lyophilized preputial matrix (LPM). Rabbits of group III (n=8) were injected with DxHA as the control group. They were followed up for 1 and 6 months after the injection. Subcutaneous injection of all bulking agents was also performed in nude mice. Biopsies were stained with LCA (leukocyte common antibody), CD68, CD31, and CD34. Scanning electron microscopy (SEM) and MTT assay were also performed. Results: Immunohistochemistry staining with CD68 and LCA revealed higher inflammation grade in LDM as compared with LPM and DxHA. Fibrosis grade was also higher in LDM both in short- and long-term follow-ups. However, no significant difference was detected in CD31 and CD34 staining between control and experimental groups. SEM analysis showed that the particle size of LPM was more similar to DxHA. MTT assay revealed that cell proliferation was similar in DxHA, LDM, and LPM. In-vivo assay in nude mice model showed more promising results in LPM as compared with LDM. Conclusion: The long-term results demonstrated that LPM was more similar to Deflux with the least local tissue reaction, inflammation, and fibrosis grade.
Descritores: Dextranos
Ácido Hialurônico
-Coelhos
Bexiga Urinária
Injeções
Camundongos
Camundongos Nus
Limites: Animais
Responsável: BR1.1 - BIREME


  6 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1150986
Autor: Andueza Galeno, Isabel Cecilia.
Título: Desarrollo de un nanosistema para la liberación de fármacos intravítreo / Development of intravitreal nanosistema for drugs release.
Fonte: Caracas; s.n; oct. 2012. ilus, tab, graf.
Idioma: es.
Tese: Apresentada a Universidad Central de Venezuela. Facultad de Farmacia para obtenção do grau de Doctor.
Resumo: La inyección intravítrea ha sido la vía de administración más eficaz para el tratamiento de enfermedades vitreorretinianas. Su práctica continua, no es agradable para los pacientes y a su vez podría causar complicaciones indeseadas. El presente trabajo tuvo como objetivo desarrollar un nanosistema de liberación polímero-terapéutico (conjugado)/nanopartícula, utilizando Dextrano y Quitosano como polímeros transportadores biodegradables, hidrosolubles y compatibles a nivel ocular así como Hemisuccinato de Metilprednisolona como fármaco modelo. Primeramente, el fármaco fue capaz de unirse covalentemente a dos Dextranos de pesos moleculares 10 y 70 kDa. En función del contenido del componente activo y perfil de liberación, se seleccionó el Hemisuccinato de Metilprednisolona-Dextrano 10 kDa para elaborar las nanopartículas de Quitosano por el método de gelificación iónica empleando tripolifosfato sódico como agente entrecruzante. Por último, las nanopartículas fueron cubiertas con lactosa aplicando el secado por atomización. Se evaluó morfología, distribución de tamaño de las partículas, carga superficial, contenido y eficacia de captura del fármaco. Las partículas esféricas presentaron superficies lisas y uniformes. El pH tuvo influencia en el tamaño de las partículas observándose una distribución bimodal a pHs ≈ pKa del Quitosano y unimodal con un rango entre 130 - 170 nm a pHs < pKa. La variación de los potenciales Zeta entre los compuestos involucrados en la reacción, indicaron la posible ocurrencia de la misma. Al comparar la liberación del conjugado con las Nanopartículas a pH fisiológico, se observó que la encapsulación retrasó la liberación del fármaco alrededor de un 50%. Las nanopartículas recubiertas formaron micropartículas de 1.780 ± 0,5 nm, lo que favoreció su dispersibilidad en agua. Este nuevo nanosistema, evidenció su posible potencial en el desarrollo de formulaciones de liberación intravítrea, que reduzca la frecuencia de administración, ofreciendo una excelente alternativa que proporcione un mayor grado de satisfacción y mejore la calidad de vida del paciente.
Descritores: Doenças Retinianas/tratamento farmacológico
Nanotecnologia/organização & administração
Liberação Controlada de Fármacos/efeitos dos fármacos
-Polímeros/farmacologia
Qualidade de Vida
Doenças Retinianas/complicações
Metilprednisolona/uso terapêutico
Cromatografia Líquida/métodos
Dextranos/uso terapêutico
Membrana Epirretiniana/tratamento farmacológico
Preparações de Ação Retardada/farmacologia
Quitosana/uso terapêutico
Composição de Medicamentos/métodos
Material Particulado/uso terapêutico
Nanopartículas/administração & dosagem
Injeções Intravítreas/efeitos adversos
Limites: Humanos
Tipo de Publ: Estudo de Validação
Responsável: VE497.1 - Biblioteca Dr. Oswaldo Enríquez Isava
VE497.1; D-CF, An3


  7 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1116432
Autor: Demirhan, Tanju; Celik, Gokcen Yuvali; Katircioglu, Hikmet; Onbasli, Dilsad.
Título: Evaluation of anti-biofouling potential of Viburnum opulus extracts / Evaluación del potencial anti bioincrustante de extractos de Viburnum opulus
Fonte: Bol. latinoam. Caribe plantas med. aromát;19(3):321-333, mayo 2020. ilus, tab.
Idioma: en.
Projeto: Erciyes University Scientific Research Projects Unit.
Resumo: In this study the in vitro investigation of the inhibitory effect of ethanol extract of Viburnum opulus L. bark sample on Streptococcus mutans planctonic cells and biofilm has been intended. A Scanning electron microscopy analysis has been performed in order to investigate the inhibitory effect of the extract on Streptococcus mutans biofilms. Furthermore, the Exopolysaccharide and dextran production of this bacteria have been identified in the presence of the extract. It has been found out that the bark extract with the concentration of 2,5 mg/mL is able to inhibit more than 50% of the cells in the different times development phases. According to this, the exopolymeric matrix on the biofilm surface disperses and the Exopolysaccharide and dextran production get lowered in the presence of bark extract compared to the control group. It is considered that this extract can be used as an alternative approach for the new chemotherapeutic strategies against tooth decay.

En este estudio se investigó el efecto inhibitorio in vitro del extracto de etanólico de una muestra de corteza de Viburnum opulus L. en biopelículas de células planctónicas de Streptococcus mutans. Se realizó un análisis de microscopía electrónica de barrido para investigar el efecto inhibitorio del extracto sobre las biopelículas de Streptococcus mutans. Además, se identificó la producción de exopolisacárido y dextrano de esta bacteria en presencia del extracto. Se descubrió que el extracto de corteza con una concentración de 2,5 mg/ml inhibió más del 50% de las células en las diferentes fases de desarrollo. Consecuentemente, la matriz exopolimérica en la superficie de la biopelícula se dispersa y la producción de exopolisacárido y dextrano se reduce en presencia de extracto de corteza en comparación con el grupo de control. Se sugiere que este extracto puede ser usado como un enfoque alternativo para las nuevas estrategias quimioterapéuticas contra la carie dental.
Descritores: Streptococcus mutans/efeitos dos fármacos
Extratos Vegetais/farmacologia
Viburnum opulus/farmacologia
Viburnum/química
-Polissacarídeos Bacterianos/análise
Streptococcus mutans/metabolismo
Técnicas In Vitro
Microscopia Eletrônica de Varredura
Dextranos/análise
Biofilmes/efeitos dos fármacos
Etanol
Incrustação Biológica
Responsável: CL1.1 - Biblioteca Central


  8 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-787333
Autor: Oltulu, Refik; Satirtav, Gunhal; Donbaloglu, Meryem; Gunduz, Mehmet Kemal; Kerimoglu, Hurkan; Okka, Mehmet; Ozkagnici, Ahmet; Karaibrahimoglu, Adnan.
Título: Six-month outcomes of corneal crosslinking with dextran-free isotonic riboflavin solution / Resultados após seis meses de crosslinking de córnea com solução isotônica de riboflavina sem dextrano
Fonte: Arq. bras. oftalmol;79(3):147-150graf.
Idioma: en.
Resumo: ABSTRACT Purpose: To analyze the short-term clinical and topographic outcomes in patients with keratoconus after corneal collagen cross-linking treatment (CXL) with dextran-free isotonic riboflavin solution. Methods: In this retrospective case series, 26 eyes from 26 patients with keratoconus were studied. The best corrected visual acuity (BCVA) and refractive and topographic findings were analyzed at a 6-month follow-up. Results: The mean BCVA (Snellen lines) values before and 1, 3, and 6 months after CXL were 0.51 ± 0.2, 0.48 ± 0.2, 0.57 ± 0.2, and 0.64 ± 0.2, respectively, and the difference between the preoperative and 6-month values was statistically significant (p=0.006). The mean spherical equivalent refraction decreased from -5.6 ± 2.4 diopters (D) preoperatively to -5.0 ± 2.1 D, and mean simulated keratometry decreased from 48.5 ± 2.5 D to 47.8 ± 2.6 D at 6 months. (p=0.145 and p=0.001, respectively). In addition, the maximum keratometry decreased progressively and significantly from the preoperative value during follow-up (p=0.003). The central and minimal corneal thicknesses, including those of the epithelium, also decreased from 442.8 ± 25.6 µm and 430.5 ± 23.9 µm preoperatively to 420.7 ± 31.8 µm and 409.3 ± 28.7 µm at the most recent follow-up (p<0.001), respectively. No intraoperative or postoperative complications were observed. Conclusions: CXL with dextran-free isotonic riboflavin solution appears to be a safe treatment alternative for keratoconus and yields sustained short-term improvements in visual acuity, keratometric readings, and corneal thickness. However, long-term results are needed to confirm these outcomes.

RESUMO Objetivo: Analisar os resultados clínicos e topográficos curto prazo após crosslinking (CXL) de córnea com solução isotônica de riboflavina sem dextrano, em pacientes com ceratocone. Método: Estudamos 26 olhos de 26 pacientes com ceratocone, nesta série retrospectiva de casos. Melhor acuidade visual corrigida (BCVA), refração e achados topográficos foram analisados aos 6 meses de acompanhamento. Resultados: BCVA pré-operatória (linhas de Snellen) foi de 0,51 ± 0,2. BCVA após CXL foram de 0,48 ± 0,2, 0,57 ± 0,2 e 0,64 ± 0,2 no 1º, 3º e 6º meses, respectivamente. A diferença entre a BCVA pré-operatória e mais recente foi estatisticamente significativa (p=0,006). O equivalente esférico médio diminuiu de -5,6 ± 2,4 dioptrias (D) no pré-operatório para -5.0 ± 2.1 D e a média da ceratometria simulada diminuiu de 48,5 ± 2,5 D para 47, 8± 2,6 D aos 6 meses. (p=0,145 e p=0,001, respectivamente). A ceratometria máxima diminuiu progressivamente durante o acompanhamento com as mudanças sendo significativamente diferentes do valor pré-operatório (p=0,003). As espessuras corneanas central e mínima, diminuiram de 442,8 ± 25,6 µm e 430,5 ± 23,9 µm para 420,7 ± 31,8 µm e 409,3 ± 28,7 µm, respectivamente, na visita mais recente (p<0,001). Não foram observadas complicações intraoperatórias e pós-operatórias. Conclusões: CXL com solução de riboflavina isotônica sem dextrano parece ser uma opção segura de tratamento para o ceratocone com melhora mantida na acuidade visual, ceratometria e espessura corneana, no curto prazo. Resultados a longo prazo são necessários para confirmar estes resultados.
Descritores: Riboflavina/uso terapêutico
Fármacos Fotossensibilizantes/uso terapêutico
Córnea/efeitos dos fármacos
Reagentes para Ligações Cruzadas/uso terapêutico
Ceratocone/tratamento farmacológico
-Acuidade Visual/efeitos dos fármacos
Reprodutibilidade dos Testes
Dextranos
Resultado do Tratamento
Fármacos Fotossensibilizantes/farmacologia
Estatísticas não Paramétricas
Córnea/patologia
Topografia da Córnea
Reagentes para Ligações Cruzadas/farmacologia
Soluções Isotônicas
Ceratocone/patologia
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME


  9 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886908
Autor: SUFIATE, BRUNA L; SOARES, FILIPPE E F; GOUVEIA, ANGÉLICA S; MOREIRA, SAMARA S; CARDOSO, EVANDRO F; TAVARES, GABRIELLA P; BRAGA, FABIO R; ARAÚJO, JACKSON V DE; QUEIROZ, JOSÉ H DE.
Título: Statistical tools application on dextranase production from Pochonia chlamydosporia (VC4) and its application on dextran removal from sugarcane juice
Fonte: An. acad. bras. ciênc;90(1):461-470, Mar. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT The aim of this study was to optimize the dextranase production by fungus Pochonia chlamydosporia (VC4) and evaluate its activity in dextran reduction in sugarcane juice. The effects, over the P. chlamydosporia dextranase production, of different components from the culture medium were analyzed by Plackett-Burman design and central composite design. The response surface was utilized to determine the levels that, among the variables that influence dextranase production, provide higher production of these enzymes. The enzymatic effect on the removal of dextran present in sugarcane juice was also evaluated. It was observed that only NaNO3 and pH showed significant effect (p<0.05) over dextranase production and was determined that the levels which provided higher enzyme production were, respectively, 5 g/L and 5.5. The dextranases produced by fungus P. chlamydosporia reduced by 75% the dextran content of the sugarcane juice once treated for 12 hours, when compared to the control treatment.
Descritores: Modelos Estatísticos
Saccharum/metabolismo
Dextranase/biossíntese
Hypocreales/enzimologia
-Temperatura
Dextranos/metabolismo
Meios de Cultura/metabolismo
Eletroforese em Gel de Poliacrilamida
Ativação Enzimática
Sucos de Frutas e Vegetais/análise
Fracionamento Químico/métodos
Concentração de Íons de Hidrogênio
Nitratos
Responsável: BR1.1 - BIREME


  10 / 111 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1040273
Autor: Ferrari, Renata Salatti; Thomaz, Leonardo Dalla Giacomassa Rocha; Simoneti, Lucas Elias Lise; Ulbrich, Jane Maria; Andrade, Cristiano Feijó.
Título: Effect of vaporized perfluorocarbon on oxidative stress during the cold ischemia phase of lung graft preservation / Efeito do perfluorocarbono vaporizado sobre o estresse oxidativo no período de isquemia fria durante a preservação pulmonar
Fonte: J. bras. pneumol;45(4):e20170288, 2019. graf.
Idioma: en.
Projeto: Fundo de Incentivo à Pesquisa (FIPE, Research Incentive Fund) of the Porto Alegre Hospital de Clínicas.
Resumo: ABSTRACT Liquid perfluorocarbon (PFC) instillation has been studied experimentally as an adjuvant therapy in the preservation of lung grafts during cold ischemia. The objective of this study was to evaluate whether vaporized PFC is also protective of lung grafts at different cold ischemia times. We performed histological analysis of and measured oxidative stress in the lungs of animals that received only preservation solution with low-potassium dextran (LPD) or vaporized PFC together with LPD. We conclude that vaporized PFC reduces the production of free radicals and the number of pulmonary structural changes resulting from cold ischemia.

RESUMO O perfluorocarbono (PFC) líquido tem sido estudado experimentalmente como uma substância adjuvante na preservação de enxertos pulmonares durante o período de isquemia fria. O objetivo deste estudo foi avaliar se o PFC vaporizado (e não instilado) também atuaria como protetor de enxertos pulmonares em diferentes tempos de isquemia fria. Realizamos análise histológica e dosamos o estresse oxidativo em pulmões de animais que receberam somente uma solução de preservação com low-potassium dextran (LPD, dextrana com baixa concentração de potássio) ou PFC vaporizado associado a LPD. Concluímos que o PFC vaporizado reduziu a produção de radicais livres e provocou menor número de alterações estruturais pulmonares decorrentes do período de isquemia fria que o uso de LPD isoladamente.
Descritores: Preservação de Órgãos/métodos
Transplante de Pulmão/métodos
Estresse Oxidativo/efeitos dos fármacos
Isquemia Fria/métodos
Fluorcarbonetos/farmacologia
Pulmão/efeitos dos fármacos
-Valores de Referência
Fatores de Tempo
Reprodutibilidade dos Testes
Dextranos/farmacologia
Soluções para Preservação de Órgãos
Glucose/farmacologia
Pulmão/patologia
Limites: Humanos
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME



página 1 de 12 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde